Ignite Creation Date:
2024-05-06 @ 7:45 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06123754
Status:
RECRUITING
Last Update Posted:
2024-01-31
First Post:
2023-10-25
Brief Title:
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
Sponsor:
3D Medicines Sichuan Co Ltd
Organization:
3D Medicines
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non-small Cell Lung Cancer |
Keywords:
| Name | View |
|---|---|
| Envafolimab | View |